Psyence BioMed, a biopharmaceutical company focused on nature-derived psilocybin and ibogaine therapies, has made a strategic equity investment in PsyLabs. Through this investment, Psyence BioMed becomes the only publicly listed psychedelics company with active operations and manufacturing capabilities based in Africa, the original source of ibogaine. The partnership strengthens Psyence BioMed's supply chain and positions the company to deliver sustainable, ethical, and science-driven psychedelic therapies to a global market. Shareholders are expected to benefit from early access to pipeline products, intellectual property development, and secure supply channels as demand for psychedelic APIs grows worldwide.